Skip to main content

Samsara BioCapital — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$14.2B
Total invested
$107.7M
Avg. check
16
Industries
Biotechnology 22Health Care 16Medical 11Therapeutics 9Life Science 6Pharmaceutical 6+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 73–96 of 132
Allakos
September 2022

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

Biopharma · Redwood City$150.0M Post-IPO Equity
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
DELFI Diagnostics
July 2022

DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.

Artificial Intelligence (AI) · Palo Alto$225.0M Series B
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
Chinook Therapeutics
May 2022

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.

Biotechnology · Vancouver$105.0M Post-IPO Equity
Ionpath
May 2022

Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies.

Biotechnology · Menlo ParkCorporate Round
Simcha Therapeutics
January 2022

Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.

Biotechnology · New Haven$40.0M Series B
Exo Therapeutics
October 2021

Exo Therapeutics is a small molecule drug discovery and development company.

Biotechnology · Cambridge$78.0M Series B
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B
Primmune Therapeutics
January 2026

Primmune Therapeutics is a Biotechnology company.

Biotechnology · San Diego$23.3M Series B
Alamar Biosciences
January 2026

Powering precision proteomics to enable to the earliest detection of disease.

Biotechnology · Fremont$50.0M Convertible Note
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
Kalaris Therapeutics (formerly AlloVir)
December 2025

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Biotechnology · Houston$50.0M Post Ipo Equity
Link Cell Therapies
December 2025

Link Cell Therapies is a biotechnology company that specializes in cancer cell therapy research and development services.

Biotechnology · San Francisco$60.0M Series A
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post Ipo Equity
Psivant Therapeutics
December 2025

Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services.

Biopharma · Watertown$47.5M Series A
Excellergy
October 2025

Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases.

Biotechnology · Palo Alto$70.0M Series A
Cypherpunk Technologies (formerly Leap Therapeutics)
October 2025

Cypherpunk is a biopharmaceutical company developing antibody therapies for cancer while executing a digital-asset treasury strategy.

Biotechnology · Cambridge$58.9M Post Ipo Equity
Enlaza Therapeutics
September 2025

Enlaza Therapeutics is a biotechnology research company.

Biopharma · La Jolla$15.0M Series Unknown
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post Ipo Equity
Abivax
July 2025

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$747.5M Post Ipo Equity
Shenandoah Therapeutics
June 2025

Shenandoah Therapeutics is a biotechnology company.

Health Care · South San Francisco$20.0M Seed
Spyglass Pharma
June 2025

Spyglass Pharma provides medicine for ophthalmic diseases.

Delivery · Aliso Viejo$75.0M Series D
Alpheus Medical
May 2025

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.

Biotechnology · Oakdale$52.0M Series B

Where Samsara BioCapital invests

Biotechnology22
Health Care16
Medical11
Therapeutics9
Life Science6
Pharmaceutical6

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?▸

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?▸

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 16 different industry categories.

What is Samsara BioCapital's largest investment?▸

Among tracked funding rounds, Abivax received $747.5M in a Post Ipo Equity round. Samsara BioCapital's total known invested capital is $14.2B.

What is the average investment size for Samsara BioCapital?▸

Samsara BioCapital's average investment size is $107.7M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?▸

Recent Samsara BioCapital portfolio additions include Allakos, ACELYRIN, DELFI Diagnostics, MiroBio, Chinook Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →